Sparks commentary - Oryzon Genomics

Healthcare

Sparks - Oryzon Genomics

More on this equity
testalize-me-0jE8ynV4mis-unsplash
Oryzon Genomics (BME: ORY) further strengthens vafidemstat’s intellectual property profile
Published by Arron Aatkar, PhD

Oryzon Genomics has received new ‘decision to grant’ communications from the Canadian Intellectual Property Office and the Israel Patent Office. This is for its patents ‘Methods of treating behavior alterations’ for lead CNS candidate, vafidemstat, as a potential treatment to address aggression and social withdrawal. Once granted, these patents will remain in force until at least 2038 in Canada and Israel, excluding any potential patent term extensions (which have the potential to add additional years of protection).

Oryzon is currently preparing for a Phase III programme, which will evaluate vafidemstat for the treatment of aggression in patients with borderline personality disorder.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.